2018-2023 Global Paroxysmal Supraventricular Tachycardia Market Report (Status and Outlook)

August 2018 | 115 pages | ID: 2488B852B91EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Paroxysmal Supraventricular Tachycardia market for 2018-2023.

Paroxysmal supraventricular tachycardia (PSVT) is a type of supraventricular tachycardia. Often people have no symptoms. Otherwise symptoms may include palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain. Episodes start and end suddenly.
About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. Problems typically begin in those 12 to 45 years old. Women are more often affected than men. Outcomes in those who otherwise have a normal heart are generally good. An ultrasound of the heart may be done to rule out underlying heart problems.
Over the next five years, LPI(LP Information) projects that Paroxysmal Supraventricular Tachycardia will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares and growth opportunities of Paroxysmal Supraventricular Tachycardia market by product type, application, key companies and key regions.

To calculate the market size, LP Information considers value generated from the sales of the following segments:

Segmentation by product type:

• AV Nodal Re-Entrant Tachycardia (AVNRT)
• AV Reciprocating Tachycardia (AVRT)
• Wolff-Parkinson-White Syndrome (WPW)

Segmentation by application:

• Hospitals & Clinics
• Diagnostic Centers
• Medical Research Centers

We can also provide the customized separate regional or country-level reports, for the following regions:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

• GlaxoSmithKline
• Sanofi
• Pfizer
• Novartis International
• Teva Pharmaceutical Industries
• Medtronic
• Glenmark Pharmaceuticals
• St. Jude Medical
• Boston Scientific

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Paroxysmal Supraventricular Tachycardia market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Paroxysmal Supraventricular Tachycardia market by identifying its various subsegments.
• Focuses on the key global Paroxysmal Supraventricular Tachycardia players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Paroxysmal Supraventricular Tachycardia with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the size of Paroxysmal Supraventricular Tachycardia submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Paroxysmal Supraventricular Tachycardia Market Size 2013-2023
  2.1.2 Paroxysmal Supraventricular Tachycardia Market Size CAGR by Region
2.2 Paroxysmal Supraventricular Tachycardia Segment by Type
  2.2.1 AV Nodal Re-Entrant Tachycardia (AVNRT)
  2.2.2 AV Reciprocating Tachycardia (AVRT)
  2.2.3 Paroxysmal Atrial Tachycardia (PAT)
  2.2.4 Wolff-Parkinson-White Syndrome (WPW)
2.3 Paroxysmal Supraventricular Tachycardia Market Size by Type
  2.3.1 Global Paroxysmal Supraventricular Tachycardia Market Size Market Share by Type (2013-2018)
  2.3.2 Global Paroxysmal Supraventricular Tachycardia Market Size Growth Rate by Type (2013-2018)
2.4 Paroxysmal Supraventricular Tachycardia Segment by Application
  2.4.1 Hospitals & Clinics
  2.4.2 Diagnostic Centers
  2.4.3 Medical Research Centers
2.5 Paroxysmal Supraventricular Tachycardia Market Size by Application
  2.5.1 Global Paroxysmal Supraventricular Tachycardia Market Size Market Share by Application (2013-2018)
  2.5.2 Global Paroxysmal Supraventricular Tachycardia Market Size Growth Rate by Application (2013-2018)

3 GLOBAL PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA BY PLAYERS

3.1 Global Paroxysmal Supraventricular Tachycardia Market Size Market Share by Players
  3.1.1 Global Paroxysmal Supraventricular Tachycardia Market Size by Players (2016-2018)
  3.1.2 Global Paroxysmal Supraventricular Tachycardia Market Size Market Share by Players (2016-2018)
3.2 Global Paroxysmal Supraventricular Tachycardia Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA BY REGIONS

4.1 Paroxysmal Supraventricular Tachycardia Market Size by Regions
4.2 Americas Paroxysmal Supraventricular Tachycardia Market Size Growth
4.3 APAC Paroxysmal Supraventricular Tachycardia Market Size Growth
4.4 Europe Paroxysmal Supraventricular Tachycardia Market Size Growth
4.5 Middle East & Africa Paroxysmal Supraventricular Tachycardia Market Size Growth

5 AMERICAS

5.1 Americas Paroxysmal Supraventricular Tachycardia Market Size by Countries
5.2 Americas Paroxysmal Supraventricular Tachycardia Market Size by Type
5.3 Americas Paroxysmal Supraventricular Tachycardia Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Paroxysmal Supraventricular Tachycardia Market Size by Countries
6.2 APAC Paroxysmal Supraventricular Tachycardia Market Size by Type
6.3 APAC Paroxysmal Supraventricular Tachycardia Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Paroxysmal Supraventricular Tachycardia by Countries
7.2 Europe Paroxysmal Supraventricular Tachycardia Market Size by Type
7.3 Europe Paroxysmal Supraventricular Tachycardia Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Paroxysmal Supraventricular Tachycardia by Countries
8.2 Middle East & Africa Paroxysmal Supraventricular Tachycardia Market Size by Type
8.3 Middle East & Africa Paroxysmal Supraventricular Tachycardia Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 GLOBAL PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA MARKET FORECAST

10.1 Global Paroxysmal Supraventricular Tachycardia Market Size Forecast (2018-2023)
10.2 Global Paroxysmal Supraventricular Tachycardia Forecast by Regions
  10.2.1 Global Paroxysmal Supraventricular Tachycardia Forecast by Regions (2018-2023)
  10.2.2 Americas Market Forecast
  10.2.3 APAC Market Forecast
  10.2.4 Europe Market Forecast
  10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
  10.3.1 United States Market Forecast
  10.3.2 Canada Market Forecast
  10.3.3 Mexico Market Forecast
  10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
  10.4.1 China Market Forecast
  10.4.2 Japan Market Forecast
  10.4.3 Korea Market Forecast
  10.4.4 Southeast Asia Market Forecast
  10.4.5 India Market Forecast
  10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
  10.5.1 Germany Market Forecast
  10.5.2 France Market Forecast
  10.5.3 UK Market Forecast
  10.5.4 Italy Market Forecast
  10.5.5 Russia Market Forecast
  10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
  10.6.1 Egypt Market Forecast
  10.6.2 South Africa Market Forecast
  10.6.3 Israel Market Forecast
  10.6.4 Turkey Market Forecast
  10.6.5 GCC Countries Market Forecast
10.7 Global Paroxysmal Supraventricular Tachycardia Forecast by Type
10.8 Global Paroxysmal Supraventricular Tachycardia Forecast by Application

11 KEY PLAYERS ANALYSIS

11.1 GlaxoSmithKline
  11.1.1 Company Details
  11.1.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.1.3 GlaxoSmithKline Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.1.4 Main Business Overview
  11.1.5 GlaxoSmithKline News
11.2 Sanofi
  11.2.1 Company Details
  11.2.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.2.3 Sanofi Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.2.4 Main Business Overview
  11.2.5 Sanofi News
11.3 Pfizer
  11.3.1 Company Details
  11.3.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.3.3 Pfizer Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.3.4 Main Business Overview
  11.3.5 Pfizer News
11.4 Novartis International
  11.4.1 Company Details
  11.4.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.4.3 Novartis International Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.4.4 Main Business Overview
  11.4.5 Novartis International News
11.5 Teva Pharmaceutical Industries
  11.5.1 Company Details
  11.5.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.5.3 Teva Pharmaceutical Industries Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.5.4 Main Business Overview
  11.5.5 Teva Pharmaceutical Industries News
11.6 Medtronic
  11.6.1 Company Details
  11.6.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.6.3 Medtronic Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.6.4 Main Business Overview
  11.6.5 Medtronic News
11.7 Glenmark Pharmaceuticals
  11.7.1 Company Details
  11.7.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.7.3 Glenmark Pharmaceuticals Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.7.4 Main Business Overview
  11.7.5 Glenmark Pharmaceuticals News
11.8 St. Jude Medical
  11.8.1 Company Details
  11.8.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.8.3 St. Jude Medical Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.8.4 Main Business Overview
  11.8.5 St. Jude Medical News
11.9 Boston Scientific
  11.9.1 Company Details
  11.9.2 Paroxysmal Supraventricular Tachycardia Product Offered
  11.9.3 Boston Scientific Paroxysmal Supraventricular Tachycardia Revenue, Gross Margin and Market Share (2016-2018)
  11.9.4 Main Business Overview
  11.9.5 Boston Scientific News

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Table Product Specifications of Paroxysmal Supraventricular Tachycardia
Figure Paroxysmal Supraventricular Tachycardia Report Years Considered
Figure Market Research Methodology
Figure Global Par